DAEWON PHARM revenue for the last year amounted to 526.00 B KRW, the most of which — 500.70 B KRW — came from its highest performing source at the moment, Restrictions, the year earlier bringing 452.80 B KRW. The greatest contribution to the revenue figure was made by South Korea — last year it brought DAEWON PHARM 516.43 B KRW, and the year before that — 467.17 B KRW.